Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

AstraZeneca : Volunteer in AstraZeneca/Oxford Coronavirus Vaccine Trial Dies in Brazil -- Update

10/21/2020 | 04:41pm EST

By Luciana Magalhaes and Samantha Pearson

SÃO PAULO -- Brazilian health regulator Anvisa said clinical trials in the country for the Covid-19 vaccine being developed by Oxford University and AstraZeneca would continue despite the death of one of the volunteers.

Oxford University said it had carried out a "careful assessment" of the case in Brazil and that "there have been no concerns about safety of the clinical trial."

AstraZeneca said in a statement that an independent assessment of the case didn't present "any concerns."

Brazil's Anvisa announced earlier Wednesday that it had been notified of the death on Monday and was investigating. It didn't give any information about the identity of the volunteer, or whether the person had taken a placebo dose or a real dose of the vaccine. Brazilian press reported that the volunteer was a 28-year-old man from Rio de Janeiro, who had died of complications from Covid-19.

"The fact that the trials were not suspended could indicate that the person took a placebo dose," said Carlos Fortaleza, an epidemiologist at São Paulo State University.

AstraZeneca's shares dropped as much as 1.7% but later pared back losses.

Brazil's federal government has set aside over $350 million to purchase the Oxford University vaccine, which will be produced and distributed by the country's Fiocruz scientific institution based in Rio. São Paulo is also developing another vaccine in partnership with Sinovac, a private Chinese company.

Write to Luciana Magalhaes at Luciana.Magalhaes@wsj.com and Samantha Pearson at samantha.pearson@wsj.com

(END) Dow Jones Newswires

10-21-20 1640ET

All news about ASTRAZENECA PLC
01:19pCanada could approve Pfizer's COVID-19 vaccine within the next week -official..
RE
12:11pIndia's economy on the rebound, government focuses on spending - finance mini..
RE
12:07pREUTERS SUMMIT-India's economy on the rebound, government focuses on spending..
RE
10:26aASTRAZENECA : Fortune or foresight? AstraZeneca and Oxford's stories clash on CO..
RE
08:15aU.K.'s Covid-19 Vaccine Program to Test Its State-Run Medical System
DJ
04:21aMerck KGaA agrees research deal with Artios for 'DNA damage' cancer drugs
RE
04:02aMerck KGaA agrees research deal with Artios for 'DNA damage' cancer drugs
RE
02:57aS.Korea shares close at record high on chip, auto boost
RE
02:17aASTRAZENECA : demonstrates growing leadership in breast cancer at SABCS with dat..
PU
01:09aASTRAZENECA : South Korea reaches deal to buy AstraZeneca's COVID-19 vaccine can..
RE
More news
Financials (USD)
Sales 2020 26 494 M - -
Net income 2020 2 998 M - -
Net Debt 2020 13 181 M - -
P/E ratio 2020 43,7x
Yield 2020 2,71%
Capitalization 136 B 137 B -
EV / Sales 2020 5,65x
EV / Sales 2021 4,92x
Nbr of Employees 70 600
Free-Float 95,7%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBearishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 122,11 $
Last Close Price 103,98 $
Spread / Highest target 54,0%
Spread / Average Target 17,4%
Spread / Lowest Target -36,5%
EPS Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC4.34%138 967
JOHNSON & JOHNSON2.15%389 985
ROCHE HOLDING AG-3.61%289 019
PFIZER, INC.8.00%226 783
NOVARTIS AG-10.86%207 948
MERCK & CO., INC.-10.03%207 033